Linked Life Data

19961955

Source:http://linkedlifedata.com/resource/pubmed/id/19961955

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
2010-2-9
pubmed:abstractText
Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1878-5832
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
88-97
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
pubmed:affiliation
Drug Development Unit, Royal Marsden Hospital, Marsden Hospital, Sutton, Surrey SM2 5PT, UK.
pubmed:publicationType
Journal Article, Review